All In Biotech

Drug Trial Radar · NCT00805194

LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer

Multicentre, Randomised, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Docetaxel Therapy Compared to Placebo Plus Standard Docetaxel Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy

Last checked: Nov 20, 2026Latest source record: Dec 5, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,314 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,314

Actual

Start

Dec 3, 2008

Primary completion

Nov 2, 2010

Study completion Nov 13, 2017

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Dec 9, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The present trial will be performed to evaluate whether BIBF 1120 in combination with standard therapy of docetaxel in patients with stage IIIB/IV or recurrent NSCLC is more effective as compared to placebo in combination with standard therapy of docetaxel. A secondary aim is to obtain safety information as well as information on quality of life of patients treated with BIBF 1120 in combination to standard therapy with docetaxel. In addition, blood will be collected for pharmacokinetic analysis.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

  • placebo plus docetaxelDrug

    placebo matching BIBF 1120 2 times daily along with standard therapy of docetaxel

  • BIBF 1120 plus docetaxelDrug

    BIBF 1120 2 times daily along with standard therapy of docetaxel

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) as Assessed by Central Independent ReviewTime frame: From randomisation until cut-off date 2 November 2010 (when 713 PFS events were observed)

Locations

210 sites in 27 countries. Site status is shown where the registry gives one.

  • LKH-Univ. Hospital Graz

    Graz, Austria

  • KH St. Vinzenz, Zams, Int. Abtlg.

    Kufstein, Austria

  • AKH d. Stadt Linz, Pulmologie

    Linz, Austria

  • Bobruisk Inter-distict

    Babruysk, Belarus

  • Brest Regional Clinical

    Brest Region, Belarus

  • Gomel Regional Clinical

    Homyel, Belarus

  • Public Health Inst. Minsk City Clinical Oncology Dispensary

    Minsk, Belarus

  • Scientific Research Minsk

    Minsk Region, Belarus

  • Mogilov Regional Oncological Dispensary

    Mogilev, Belarus

  • Vitebsk Regional Clinical Oncology Dispensary

    Vitebsk, Belarus

  • Centre Hospitalier Universitaire de Liège

    Liège, Belgium

  • Liège - HOSP CHR de la Citadelle

    Liège, Belgium

  • Multiprofile Hospital for Active Treatment

    Gabrovo, Bulgaria

  • Univ.Multiprofile Hospital "Dr. Georgy Stranski" EAD, Pleven

    Pleven, Bulgaria

  • District Oncology Dispensary Plovdiv

    Plovdiv, Bulgaria

  • Interdistrict Oncology Dispensary, Ruse

    Rousse, Bulgaria

  • District Oncology Dispensary Shumen

    Shumen, Bulgaria

  • Specialized Hospital for Active Treatment in Oncolcogy

    Sofia, Bulgaria

  • 307 Hospital of PLA

    Beijing, China

  • Jilin Province Cancer Hospital

    Changchun, China

  • First Hospital of Jilin University

    Changchun, China

  • West China Hospital

    Chengdu, China

  • Southwest Hospital

    Chongqing, China

  • First Affiliated Hospital of Dalian Medical University

    Dalian, China

  • The Second Affiliated Hospital of Dalian Medical University

    Dalian, China

  • Fujian Provincial Tumor Hospital

    Fujian, China

  • Sun Yat-Sen University Cancer Center

    Guangzhou, China

  • Guangdong General Hospital

    Guangzhou, China

  • Sir Run Run Shaw Hospital

    Hangzhou, China

  • Zhejiang Cancer Hospital

    Hangzhou, China

  • The Third Affiliated Hospital of Harbin Medical University

    Harbin, China

  • the 81th Hospital of PLA

    Nanjing, China

  • Jiangsu Cancer Hospital

    Nanjing, China

  • Shanghai Chest Hospital

    Shanghai, China

  • Fudan University Shanghai Cancer Center

    Shanghai, China

  • Shanghai Pulmonary Hospital

    Shanghai, China

  • Tongji Hospital, Tongji University

    Wuhan, China

  • Zhongshan Hospital Fudan University

    Xuhui Area, Shanghai, China

  • Clinical Hospital Centar Sestre Milosrdnice

    Zagreb, Croatia

  • UHC Zagreb

    Zagreb, Croatia

Showing 40 of 210 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.